Levy Richard S 4

Accession 0001628280-25-052411

CIK 0001157601other

View on SEC.gov Company Profile

Filed

Nov 13, 7:00 PM ET

Accepted

Nov 14, 5:12 PM ET

Size

33.3 KB

Accession

0001628280-25-052411

Insider Transaction Report

Form 4

Period: 2025-11-13

MADRIGAL PHARMACEUTICALS, INC.MDGL

Levy Richard S

Director

Transactions

Exercise/Conversion
Common Stock
2025-11-13$7.36/sh+2,500$18,400→ 23,697 total
Sale
Common Stock
2025-11-13$514.67/sh−146$75,142→ 29,551 total
Sale
Common Stock
2025-11-13$517.51/sh−645$333,796→ 27,987 total
Sale
Common Stock
2025-11-13$521.79/sh−1,094$570,836→ 24,395 total
Sale
Common Stock
2025-11-13$522.70/sh−1,434$749,557→ 22,961 total
Sale
Common Stock
2025-11-13$527.85/sh−200$105,570→ 21,677 total
Sale
Common Stock
2025-11-13$530.21/sh−40$21,208→ 21,197 total
Sale
Common Stock
2025-11-13$520.68/sh−308$160,369→ 25,489 total
Sale
Common Stock
2025-11-13$523.66/sh−811$424,687→ 22,150 total
Sale
Common Stock
2025-11-13$524.49/sh−153$80,247→ 21,997 total
Sale
Common Stock
2025-11-13$528.60/sh−440$232,586→ 21,237 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-13−6,000→ 4,000 total
Exercise: $16.46Exp: 2027-06-29→ Common Stock (6,000 underlying)
Sale
Common Stock
2025-11-13$515.64/sh−919$473,876→ 28,632 total
Sale
Common Stock
2025-11-13$519.67/sh−1,355$704,147→ 25,797 total
Sale
Common Stock
2025-11-13$526.68/sh−120$63,202→ 21,877 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-13−2,500→ 2,500 total
Exercise: $7.36Exp: 2026-08-11→ Common Stock (2,500 underlying)
Exercise/Conversion
Common Stock
2025-11-13$16.46/sh+6,000$98,760→ 29,697 total
Sale
Common Stock
2025-11-13$518.53/sh−835$432,974→ 27,152 total

Footnotes (15)

[F1]These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025.
[F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $523.31 to $524.29, inclusive.
[F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $524.31 to $524.71, inclusive.
[F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.17 to $527.09, inclusive.
[F13]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.17 to $528.15, inclusive.
[F14]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.18 to $528.94, inclusive.
[F15]The shares underlying this option are fully vested and exercisable.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.03 to $514.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.19 to $516.10, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.15 to $518.10, inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.155 to $519.04, inclusive.
[F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.18 to $520.15, inclusive.
[F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.21 to $521.18, inclusive.
[F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.22 to $522.21, inclusive.
[F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $522.30 to $523.29, inclusive.

Documents

1 file

4
wk-form4_1763158342.xmlPrimary
FORM 4

Issuer

MADRIGAL PHARMACEUTICALS, INC.

CIK 0001157601

→

Entity typeother

Related Parties

filerCIK 0001454983

Filing Metadata

Form type: 4
Filed: Nov 13, 7:00 PM ET
Accepted: Nov 14, 5:12 PM ET
Size: 33.3 KB

View on SEC.gov